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Purpose: The role of vascular endothelial growth factor (VEGF)-B in the eye is poorly understood. The present study
was conducted to evaluate the effect of overexpression of VEGF-B via adeno-associated virus (AAV) gene transfer on
ocular angiogenesis, inflammation, and the blood-retinal barrier (BRB).
Methods: Three recombinant AAV vectors were prepared, expressing the 167 (AAV-VEGF-B167) or 186 amino acid
isoform (AAV-VEGF-B186) of VEGF-B or the green fluorescent protein (GFP) reporter gene (AAV-GFP). Approximately
1×109 viral genome copies of AAV-VEGF-B167, AAV-VEGF-B186, or AAV-GFP were intraocularly injected. The efficacy
of the gene transfer was assessed by directly observing GFP, by immunohistochemistry, or by real-time PCR. A leukostasis
assay using fluorescein isothiocyanate-conjugated Concanavalin A was used to evaluate inflammation. The BRB was
assessed using a quantitative assay with 3H-mannitol as a tracer. Retinal neovascularization (NV) was assessed at postnatal
day 17 in oxygen-induced ischemic retinopathy after intravitreal injection of AAV-VEGF-B in left eyes and AAV-GFP in
right  eyes  at  postnatal  day  7.  Two  weeks  after  injection  of  AAV  vectors,  choroidal  NV  was  generated  by  laser
photocoagulation and assessed 2 weeks later.
Results: GFP expression was clearly demonstrated, primarily in the retinal pigment epithelium (RPE) and outer retina,
1–6 weeks after delivery. mRNA expression levels of VEGF-B167 and VEGF-B186 were 5.8 and 12 fold higher in the
AAV-VEGF-B167-  and  AAV-VEGF-B186-treated  groups,  respectively.  There  was  no  evidence  of  an  inflammatory
response or vessel abnormality following injection of the vectors in normal mice; however, VEGF-B increased retinal and
choroidal neovascularization. AAV-VEGF-B186, but not AAV-VEGF-B167, enhanced retinal vascular permeability.
Conclusions: VEGF-B overexpression promoted pathological retinal and choroidal NV and BRB breakdown without
causing  inflammation,  which  is  associated  with  the  progression  of  diabetic  retinopathy  and  age-related  macular
degeneration, showing that these complications are not dependent on inflammation. VEGF-B targeting could benefit
antiangiogenic therapy.
Members  of  the  vascular  endothelial  growth  factor
(VEGF) family have been identified as key molecules in the
development of many of the adverse effects of retinopathy of
prematurity  (ROP),  diabetic  retinopathy  (DR),  age-related
macular  degeneration  (AMD),  and  other  ischemic  and
inflammatory  retinopathies.  The  complications  that  are
attributable, at least in part, to VEGF include retinal and
choroidal  neovascularization  (CNV)  and  other  vascular
abnormalities, blood-retinal barrier (BRB) breakdown, and
increased leukostasis.
Three members of the VEGF receptor family have been
identified:  VEGFR1,  2,  and  3  [1].  Each  of  these  distinct
tyrosine kinase receptors binds only certain VEGF family
members. Ligands of VEGFR1 include VEGF-A, VEGF-B,
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and  placental  growth  factor  (PlGF);  ligands  of  VEGFR2
include VEGF-A, VEGF-C, and VEGF-D; and the ligands of
VEGFR3 are VEGF-C and VEGF-D; thus, PlGF and VEGF-
B  uniquely  bind  VEGFR1,  and  VEGF-E  uniquely  binds
VEGFR2 [2-6]. In human and monkey retinas, all three VEGF
receptors  are  expressed  in  nonvascular  areas,  but  only
VEGFR1 is constitutively expressed in retinal microvessels,
predominantly on pericytes [2,7-10].
There is some confusion regarding the role of VEGF in
BRB breakdown and neovascularization (NV) in ischemic
retinopathies. There is strong evidence suggesting that VEGF
is the primary cytokine causing vascular leakage and NV in
ischemic retinas [2,11-15], but there is mRNA and protein
expression of VEGF-A, VEGFR1, and VEGFR2 in normal
retinas,  suggesting  physiologic  functions  for  VEGF  [2,
16-19]. VEGF is a secreted protein, so it may have paracrine,
as well as autocrine effects [20]. VEGFR1 is believed to
function in inflammation [21], but there is also convincing
evidence  that  angiogenesis  and  vascular  permeability  are
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492regulated, directly or indirectly, through VEGFR1 [22]. Most
of the biologic functions attributed to VEGF-A appear to be
mediated  through  VEGFR2,  with  the  roles  of  the  other
receptor  types  being  less  clear  [2,7,23].  The  function  of
VEGFR1 remains controversial, but there is evidence that it
can function as a negative regulator of VEGFR2 [24]. Soluble
forms of VEGFR1 and R2 also exist, and some of these splice
variants  have  specificities  different  from  those  of  the
membrane-bound forms [25-27].
PlGF is a member of the VEGF family that binds to
VEGFR1,  but  not  VEGFR2.  This  factor  can  stimulate
pathological, but not physiologic angiogenesis [28-32], and
the migration and proliferation of endothelial cells [28]. It
potentiates the effect of VEGF on vascular permeability [9,
30,33,34], and it can induce chemotaxis of monocytes, which
express  VEGFR1,  but  not  VEGFR2  [22,29,34-36].  These
findings show that PlGF plays a role in angiogenesis and
inflammation, both of which are hallmarks of DR and AMD,
but unlike VEGF, PlGF is not upregulated by hypoxia [37].
Prenatal vascular development in mice is unaffected by a PlGF
deficiency. However, our previous findings demonstrate that
anti-PlGF treatment inhibits retinal and choroidal NV, BRB
breakdown, and inflammation in experimental models [22],
providing support for the possibility that PlGF, through its
binding to VEGFR1, participates in the development of these
complications of ocular disorders. A deficiency in PlGF or the
neutralization of VEGFR1 suppressed laser-induced CNV,
reduced inflammation, and reduced retinal NV in oxygen-
induced  ischemic  retinopathy  (OIR)  [29,30,38],  as  did
deletion of the hypoxia response element from the VEGF
promoter  [39].  It  is  not  clear  whether  PlGF  stimulates
pathological  angiogenesis  and  vascular  permeability  by
signaling through VEGFR1 or by displacing VEGF-A from
VEGFR1, thereby increasing the fraction available to activate
VEGFR2 [9]. Nonetheless, depletion of PlGF clearly inhibits
these complications in experimental models of ocular disease.
Despite its early discovery and high sequence homology
to the other VEGF family members, the biologic function of
VEGF-B remained debatable for a long time. VEGF-B, like
PlGF, binds to VEGFR1, but not VEGFR2. It has a wide tissue
distribution, with the greatest abundance in the heart, skeletal
muscles,  and  diaphragm  [40,41];  however,  the  VEGF-B
promoter  lacks  a  hypoxia  response  element,  so  it  is  not
induced by hypoxia as VEGF-A is [33]. Neither VEGF-B nor
PlGF  were  able  to  compensate  for  VEGF-A  during  its
blockade, and mice lacking either factor displayed only minor
developmental defects [42]. VEGF-B knockout mice were
viable and fertile, but had subtle cardiac abnormalities [43,
44]. There are two isoforms of VEGF-B (VEGF-B167 and
VEGF-B186)  due  to  alternative  splicing  [45,46].  The
predominant isoform, VEGF-B167, which is four times more
abundant than VEGF-B186, has a COOH-terminal heparin-
binding domain, allowing it to bind to pericellular heparin-
like glycosaminoglycans, thus anchoring it to the extracellular
matrix [46].
Contrasting  results  were  obtained  by  analyzing  the
angiogenic  effects  of  VEGF-B  in  normal  and  pathologic
conditions,  with  some  studies  showing  that  VEGF-B  is
angiogenic [47-50] and others reporting that it is not [42,44,
51-53].  In  particular,  VEGF-B167  was  reported  to  have
significantly  increased  revascularization  of  the  infarcted
myocardium; however, it failed to enhance vascular growth
in  the  skin  or  ischemic  limb  [54].  Another  recent  study,
involving the delivery of VEGF-B186 after infarction in pigs
and  rabbits,  indicated  that  the  factor  induced  myocardial-
specific  angiogenesis  and  arteriogenesis  [55].  This  study,
however, used gene transfer with adenoviral vectors, which
notoriously induce inflammation and an immune response.
Finally,  gene  delivery  of  VEGF-B167  to  the  heart  using
adeno-associated vectors (AAVs) has shown that the factor
has a marked beneficial effect after myocardial infarction in
rats [56] or pacing-induced heart failure in dogs [57], in the
absence of a significant angiogenic effect. Another recent
study showed that VEGF-B was not essential for the growth
of new vessels, but it was critical for their survival [58],
affecting endothelial cells, pericytes, smooth muscle cells, and
vascular progenitor cells. Through the use of AAV vectors,
the present study was conducted to investigate the effect of
continuous expression of both isoforms of VEGF-B directly
on the retina.
METHODS
Production,  purification,  and  characterization  of
recombinant  adeno-associated  virus  vectors:  Three
recombinant  AAV  vectors  expressing  green  fluorescent
protein (GFP) and the 167 and 186 amino acid isoforms of
mouse  VEGF-B  (AAV-GFP,  AAV-VEGF-B167,  and  AAV-
VEGF-B186, respectively) were prepared by the AAV Vector
Unit at ICGEB Trieste. All the vectors were pseudotyped
following a cross-packaging approach whereby the AAV type
2 vector genome was packaged into AAV capsid serotype 9
[59,60].  Methods  for  production  and  purification  were
previously described [61,62]. Briefly, viral vector stocks were
obtained in HEK293 cells by high-scale calcium phosphate
co-precipitation of the AAV backbone plasmid along with
helper plasmids, expressing the AAV genes coding for the
replicative  and  capsid  proteins  and  the  adenovirus  helper
functions supporting AAV replication. Viral vector particles
were then purified from crude cell lysates by cesium chloride
gradient ultracentrifugation followed by dialysis of pooled
fractions. Among the different serotypes that were used for
retinal gene delivery, AAV serotype 9 (AAV9) showed robust
and widespread transduction in the outer retina, inner retina,
retinal ganglion cell (RGC) layers [63,64], and synaptic layers
[65,66]. Based on these results, we decided to develop an
AAV9-based vector for VEGF-B expression in the retina in
our  experimental  settings.  The  vectors  used  in  this  study
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493express the exogenous gene under the control of the strong,
constitutive,  immediate  early  promoter  from  the  human
cytomegalovirus (CMV).
Mice for gene transduction studies: Pathogen-free C57BL/6
mice  from  Charles  River  Laboratories  (Wilmington,  MA)
were treated in accordance with the Association for Research
in  Vision  and  Ophthalmology  Statement  for  the  Use  of
Animals in Ophthalmic and Vision Research, the guidelines
of  the  Johns  Hopkins  University  Animal  Care  and  Use
Committee, and the guidelines of the Institute for Laboratory
Animal Research (Guide for the Care and Use of Laboratory
Animals).
Intraocular injections of adeno-associated virus vectors in
mice: Subretinal or intravitreous injections were administered
with a Harvard pump microinjection apparatus and pulled
glass micropipets, as previously described [67]. Briefly, under
a dissecting microscope, the sharpened tip of a micropipette
was passed through the sclera, just behind the limbus into the
vitreous cavity. Each micropipet was calibrated to deliver
1 μl of vehicle containing approximately 1×109 viral genome
copies (vgc) of AAV-VEGF-B167, AAV-VEGF-B186, or AAV-
GFP, upon depression of a foot switch.
Real-time PCR: Total RNA was isolated from retinas using
the  RNeasy  Mini  Kit  (Qiagen,  Alameda,  CA),  and  RNA
quality  was  measured  using  a  NanoDrop1000
spectrophotometer (Thermo Scientific, Waltham, MA). The
cDNA  was  prepared  using  the  SuperScript  First-Strand
Synthesis System (Invitrogen, Carlsbad, CA), then used as a
template  for  real-time  PCR  amplification  to  detect  the
expression levels of murine VEGF-B167 and 186. Real-time
PCR was performed using iQ SYBR Green Supermix and
MyiQ  Single-Color  Real-Time  PCR  Detection  System
(BioRad, Hercules, CA). The forward and reverse primers that
were used are shown in Table 1. All primers were synthesized
by Integrated DNA Technologies (Coralville, IA). Five serial
eightfold dilutions of one of the samples were used to establish
a standard curve in each experiment with the primer Actb (β-
actin). The expression level of each gene was normalized to
that of Actb. Samples were prepared in at least triplicate, and
real-time  PCR  measurement  of  each  sample  was  done  in
triplicate.  The  formation  of  a  single  product  was  also
confirmed by observing the melting-curve graph that was
generated by the thermal cycler machine, MyiQ, for each
reaction  tube.  Agarose  gel  electrophoresis  was  used  to
confirm that reaction products had the expected size.
Fluorescence microscopy after subretinal injection of AAV-
GFP: To verify the expression of AAV vectors in retinas, 1
to 6 weeks after subretinal injection of the AAV-GFP vector
or phosphate buffered saline (PBS; 137 mM NaCl, 2.7 mM
KCl,  8  mM  Na2HPO4,  and  2  mM  KH2PO4),  mice  were
humanely  sacrificed  and  eyes  were  rapidly  removed  and
immersed in 10% formalin for at least 3 h at room temperature.
Some eyes were used to make choroidal or retinal flatmounts,
the  others  for  preparing  cryosections.  To  prepare  retinal
flatmounts, the anterior segments of eyes were removed and
the entire retina was carefully dissected from the remaining
eyecups. Radial cuts were made from the edge to the equator
of the retina, and the retina was flatmounted in aquamount
(Thermo  Fisher  Scientific,  Waltham,  MA)  with  the
photoreceptors facing down. For choroidal flatmounts, radial
cuts were also made in the remaining eyecups, which were
flatmounted  with  the  sclera  facing  down.  To  prepare
cryosections,  the  cornea  and  lens  were  removed  and  the
eyecups were cryoprotected in 20% sucrose in PBS overnight
at  4  °C.  Eyes  were  then  embedded  in  optimal  cutting
temperature embedding compound (OCT; Miles Diagnostics,
Elkhart, IN) and frozen in a slurry of dry ice and isopentane.
Ten-micron frozen sections were cut, then dried in air for 20
min, rinsed in PBS, and mounted with aquamount containing
0.2 μg/ml 4´, 6-diamidino-2´-phenylindole, dihydrochloride.
Flatmounts and sections were examined using fluorescence
microscopy (Axioskop microscope; Zeiss, Thornwood, NY),
and images were digitized using a three-color charge-coupled
device video camera (IK-TU40A; Toshiba, Tokyo, Japan) and
a frame grabber.
Immunofluorescence staining for vascular endothelial growth
factor-B:  Mice  treated  with  a  subretinal  injection  were
humanely killed after 4 weeks, and the eyes were removed and
fixed with 4% paraformaldehyde in PBS for 15 min. Then, the
anterior segments were removed, and the remaining posterior
retina was immersed again in a 4% paraformaldehyde solution
at 4 °C overnight. Eyes were sequentially washed with PBS
and 12.5% and 25% sucrose, and then embedded in OCT. Ten-
micron frozen sections were cut, air dried, and washed with
PBS. Specimens were blocked with 10% normal goat serum
in PBS for 30 min at room temperature to prevent nonspecific
binding. The slides were incubated with a 1:50 dilution of
mouse monoclonal antihuman/antimouse VEGF-B antibody
(MAB751; R&D), which identifies both VEGF-B isoforms,
in  2%  normal  goat  serum  /PBS  overnight  at  4  °C  in  a
humidified chamber, then washed with PBS three times, 5 min
TABLE 1. PRIMERS USED FOR REAL-TIME PCR
Genebank Primers Forward Reverse Size (bp) Species
NM_011697 VEGF-B167 CCTGGAAGAACACAGCCAAT GGAGTGGGATGGATGATGTC 164 mouse
NM_011697.2 VEGF-B186 CCAGACAGGGTTGCCATA GCTGGAGTGGGATGGATG 110 mouse
NM_007393.2 β-actin GCCTTCCTTCTTGGGTATGG GCAATGATCTTGATCTTCATGG 204 mouse
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494each time, and incubated with Alexa Fluor 594 goat antimouse
IgG (H+L) secondary antibody (Molecular Probes, Carlsbad,
CA) for 1.5 h at 37 °C. After washing, the slides were mounted
with  aquamount  containing  0.2  μg/ml  4´,  6-diamidino-2´-
phenylindole,  dihydrochloride.  For  a  parallel  negative
control,  the  primary  antibody  was  omitted  and  PBS  was
substituted.  Sections  were  examined  using  fluorescence
microscopy  (Axioskop  microscope;  Zeiss)  and  confocal
microscopy (Zeiss LSM 710), and images were taken under
the same conditions for optimal comparison.
Histological examination: Four weeks after vector injections
into  4-week-old  normal  C57BL/6J  mice,  mice  from  each
group  were  euthanized.  Cryosections  were  prepared  as
described  above.  Eyes  were  serially  sectioned  at  10  μm
thickness, mounted onto Superfrost/Plus microscope slides
(Fisher Scientific, Pittsburgh, PA), stained with hematoxylin
and eosin, and examined by light microscopy.
Quantitative measurement of leukostasis: Leukocytes were
labeled  with  fluorescein  isothiocyanate  (FITC)-conjugated
Concanavalin A (Vector Labs, Burlingame, CA) as previously
described  [68].  Briefly,  mice  were  perfused  with  PBS  to
remove erythrocytes and non-adherent leukocytes, followed
by a perfusion with fluorescein-conjugated concanavalin A to
label leukocytes. Another PBS perfusion was used to flush out
unbound fluorescein. Retinal flatmounts were prepared and
examined with the Axioskop microscope. The total numbers
of leukocytes adhering to the retinal vessels were counted at
200× by the same investigator, with the investigator being
masked as to the nature of the specimen.
Quantitative  assessment  of  the  blood–retinal  barrier:
Quantitative measurement of the breakdown of the BRB was
performed  as  previously  described  [68,69].  Briefly,  mice
subretinally  injected  with  AAV-VEGF-B167,  AAV-VEGF-
B186, or AAV-GFP control vector were sedated and given an
intraperitoneal  injection  of  1  μCi/g  bodyweight  of  [3H]-
mannitol after 4 weeks. One hour after injection, the mice
were sedated, retinas were rapidly removed and dissected to
free them from the lens, vitreous, and any retinal pigment
epithelium (RPE) that has been extruded. The retinas were
then placed into preweighed scintillation vials. The thoracic
cavity was opened, and the left superior lobe of the lung was
removed,  blotted  to  remove  excess  blood,  and  placed  in
another preweighed scintillation vial. A left dorsal incision
was made, and the retroperitoneal space was entered without
entering the peritoneal cavity. The renal vessels were clamped
with a forceps, and the left kidney was removed, cleaned of
all fat, blotted, and placed into a preweighed scintillation vial.
The  remaining  droplets  on  the  tissues  were  allowed  to
evaporate for 20 min. The vials were weighed, and the tissue
weights  were  calculated  and  recorded.  One  ml  of  NCSII
solubilizing solution was added, and the vials were incubated
overnight in a 50 °C water bath. The solubilized tissue was
brought  to  room  temperature  and  decolorized  with  20%
benzoyl peroxide in toluene in a 50 °C water bath. After re-
equilibrating it to room temperature, 5 ml of Cytoscint ES
(Fisher Scientific) and 30 μl of glacial acetic acid (Sigma, St.
Louis, MO) were added, and the vials were stored for several
hours in darkness at 4 °C to eliminate chemoluminescence.
Radioactivity  was  counted  with  a  Wallac  1409  Liquid
Scintillation Counter. The CPM/mg tissue measured for the
lungs, kidneys, and retinas from the experimental and control
groups was used to calculate the retina-to-lung (RLLR) and
retina-to-renal leakage ratios (RRLR). The ratios obtained for
retinas treated with AAV-VEGF-B167 or AAV-VEGF-B186
were compared with those treated with AAV-GFP control
vectors  by  Student’s  unpaired  t  test  for  populations  with
unequal variances.
Animal  model  of  oxygen-induced  ischemic  retinopathy:
Postnatal  day  7  (P7),  C57BL/6J  mice  were  given  an
intravitreal  injection  of  1  μl  of  vehicle  containing
approximately 1×109 vgc of AAV-GFP, AAV-VEGF-B167, or
AAV-VEGF-B186 and placed in a 75% oxygen box for 5 days.
At P12, the mice were returned to room air. At P17, the mice
were humanely sacrificed. Eyes were enucleated and fixed in
4%  paraformaldehyde  for  30  min  at  room  temperature.
Retinas  were  dissected  and  stained  overnight  at  room
temperature  with  fluoresceinated  Griffonia  Simplicifolia
Isolectin  B4  (Alexa  Fluor  594–conjugated  I21413;  1:100
dilution; Molecular Probes) in PBS. Following three washes,
the  retinas  were  whole-mounted  onto  Superfrost/  Plus
microscope slides with the photoreceptor side down.
Quantification of retinal NV was performed as described
previously  [70,71].  Briefly,  images  of  each  of  the  four
quadrants  of  whole  mounted  retinas  were  taken  at  5×
magnification on a Zeiss Axioplan 2 microscope and imported
into Adobe Photoshop (Adobe Systems, Inc., San Jose, CA).
Retinal segments were merged to produce an image of the
entire retina. Neovascular tuft formation was quantified by
comparing the number of pixels in the affected areas with the
total number of pixels in the retina. Percentages of NV from
mouse retinas treated with AAV-VEGF-B167 or 186 were
compared  with  those  from  the  retinas  treated  with  AAV-
GFP.  Measurement  of  retinal  NV  was  done  blind  to  the
identity of the sample.
Animal model of laser-induced choroidal neovascularization:
Two weeks after vector injection, Bruch’s membrane was
ruptured by laser photocoagulation at three locations in each
eye as previously described [72]. Briefly, C57BL/6 mice were
anesthetized  with  ketamine  hydrochloride  (100  mg/kg
bodyweight),  and  their  pupils  were  dilated.  Laser
photocoagulation (75 μm spot size, 0.1 s duration, 120 mW)
was performed in the 9, 12, and 3 o’clock positions of the
posterior pole of each eye with the slit-lamp delivery system
of an OcuLight GL diode laser (Iridex, Mountain View, CA),
and a handheld coverslip was used as a contact lens to view
the retina. Production of a tissue bubble by the laser, which
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495indicates  ruptures  of  Bruch’s  membrane,  is  an  important
factor in obtaining CNV; therefore, only burns in which a
bubble was produced were included in the study.
After 2 weeks, the mice were perfused with 1 ml of PBS
containing 50 mg/ml of fluorescein-labeled dextran (2×106 Da
average molecular mass; Sigma-Aldrich, St. Louis, MO), and
choroidal  flatmounts  were  examined  by  fluorescence
microscopy. Images were captured at 20× magnification on a
Zeiss  Axioplan  2  microscope.  Image  analysis  software
(Image-Pro Plus; Media Cybernetics, Silver Spring, MD) was
used to measure the total area of CNV at each rupture site,
with the investigator masked with respect to treatment group.
This is a widely used and accepted method for assessing
experimental CNV [72,73].
Statistical  analysis  to  determine  significance:  Data  were
expressed as mean±SEM. Statistical analysis was performed
using Student’s t test; p<0.05 was considered significant.
RESULTS
Construction  and  characterization  of  recombinant  adeno-
associated virus vectors: Three vectors based on the AAV
serotype 9 (AAV9) were constructed, respectively, expressing
the 167 and 186 amino acid isoforms of mouse VEGF-B
(AAV-VEGF-B167  and  AAV-VEGF-B186)  or  the  green
fluorescence protein gene (AAV-GFP) under the control of the
human  CMV  promoter  (Figure  1A).  For  the  three  vector
preparations, titers were approximately 1.0×1012 vgc/ml.
Transgene expression of recombinant adeno-associated virus
vectors in the mouse retina: To determine the location and the
time course of rAAV expression in mouse retinas, 4-week-old
C57BL/6J mice received subretinal injections of AAV-GFP or
PBS. Animals were killed 1–6 weeks after injection. Under
fluorescence  microscopy,  GFP  expression  was  clearly
demonstrated at 4 weeks postinjection, primarily in the RPE
and the outer retina (Figure 1B-D) in mice treated with 108 or
109 vgc, but not 107 or 106 vgc, of the AAV-GFP vector,
whereas  animals  injected  with  PBS  showed  no  green
fluorescence during the 1 to 6 weeks after subretinal injection.
GFP expression was maximal at 4 weeks.
Analogous results were obtained by subretinal injection
with  the  AAV  vectors  expressing  VEGF-B167  and  186.
Immunofluorescence performed with the mouse monoclonal
antibody reacting with both isoforms of mouse VEGF-B at 4
weeks after injection showed that expression of VEGF-B167
(Figure 1E) or VEGF-B186 protein (Figure 1F) was greater
in retinas of AAV-VEGF-B injected mice, mainly in the RPE,
outer  segments  (OS),  outer  plexiform  layer  (OPL),  inner
nuclear layer (INL), inner plexiform layer (IPL), ganglion cell
layer (GCL), and endothelial cells than in mice from the GFP
control group (Figure 1G). Data was not shown for the other
time points. Real-time PCR assay further confirmed that the
mRNA expression levels of VEGF-B167 (Figure 1H) and 186
(Figure 1I) in treated groups were significantly higher (5.8
fold and 12-fold respectively) than in the AAV-GFP control
group.  Administration  of  108  vgc  or  less  of  AAV-VEGF-
B167 or 186 did not result in increased expression, probably
because this was a subthreshold level or because the increase
in expression was too small for our assay to detect. Our data
for GFP expression was similar to those of previous reports
[74,75]; therefore, the same dosage of 109 vgc/μl of AAV
vectors was used for all ensuing experiments.
Neither  VEGF-B167  nor  186  induced  an  obvious
inflammatory response: Based on published references and
our  own  studies,  VEGF-A  notably  induced  not  only
neovascularization, but also an inflammatory response and
vasopermeability  [68,76-78].  Therefore,  we  questioned
whether  intraocular  overexpression  of  both  isoforms  of
VEGF-B  would  induce  similar  inflammatory  effects.
Hematoxylin and eosin staining did not show evidence of
inflammatory cell infiltration or edema on retinal sections
from the control and experimental groups (Figure 2A-C) and
the  retinas  and  their  vasculature  had  relatively  normal
configuration.
To  determine  more  definitively  the  inflammatory
response to VEGF-B167 and 186, a leukostasis assay was
performed and the numbers of leukocytes adherent to retinal
vessels were counted. Four weeks after subretinal injection of
AAV-vectors,  neither  AAV-VEGF-B167  nor  AAV-VEGF-
B186 caused significant leukostasis compared to AAV-GFP
controls  (AAV-VEGF-B167:  8.8±0.9  adherent  leukocytes/
retina,  n=10;  AAV-VEGF-B186:  7.75±1.2  adherent
leukocytes/retina,  n=8;  AAV-GFP:  7.3±0.9  adherent
leukocytes/retina,  n=10;  PVEGF-B167/GFP=0.14;  PVEGF-B186/
GFP=0.38)  (Figure  2D-G).  A  comparative  image  showing
VEGF-A-induced retinal leukostasis is shown in Figure 2H.
Overexpression  of  VEGF-B186,  but  not  VEGF-B167,
significantly increased vasopermeability of the retina: Our
previous experiments have demonstrated that determining the
amount of [3H]-mannitol that enters the retina from the blood,
relative to the amount that enters from the lung or kidney, is
a sensitive and reproducible technique for quantifying the
breakdown of the BRB [55]. Mice treated with a subretinal
injection of AAV-VEGF-B167 showed that the RLLR (Figure
3A) and RRLR (Figure 3B) were 1.44±0.5 (n=8) and 1.48±0.5
(n=8), respectively, which was almost a threefold increase.
This was not statistically different compared to those ratios
from the AAV-GFP control mice (RLLR: 0.55±0.13, n=5;
RRLR: 0.52±0.09, n=7; PRLLR=0.10; PRRLR=0.05). However,
mice  treated  with  AAV-VEGF-B186  showed  an  RLLR  or
RRLR of 2.58±0.86 (n=7) or 1.92±0.61 (n=9), respectively,
about a four- to fivefold increase that was statistically different
compared to those ratios from the AAV-GFP control mice
(PRLLR=0.04; PRRLR=0.03).
Both  VEGF-B167  and  VEGF-B186  increased  choroidal
neovascularization: To determine whether the overexpression
of VEGF-B would provide any increase in NV, we compared
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496Figure 1. This figure shows the transgene expression of recombinant adeno-associated virus (rAAV) vectors in the retinas of 4-week-old
C57BL/6J mice, 4 weeks after subretinal injection of approximately 1×109 vgc recombinant adeno-associated virus vectors. A: This shows
the schematic representation of the three rAAV vectors used in this study for transducing vascular endothelial growth factor (VEGF)-B167,
VEGF-B186, and the marker GFP gene. Terminal repeats (TR), AAV terminal repeats; cytomegalovirus (CMV), human cytomegalovirus
immediate–early promoter; pA, polyadenylation site. B–D: Expression of GFP protein is demonstrated in flatmounts of the choroid (B), retina
(C), and a section of eye (D); note the greatest expression of green fluorescent protein (GFP) in the retinal pigment epithelium (RPE; B and
D, red arrow) and the outer retina (C and D, black arrow). E–G: Immunofluorescence staining indicated that the VEGF-B167 (E) and VEGF-
B186 proteins (F) are more strongly expressed in retinas from experimental groups—mainly in the RPE—than in retinas from the GFP control
group (G). Cell nuclei were stained with 4´, 6-diamidino-2´-phenylindole dihydrochloride. Images E–G were taken under the same conditions
for optimal comparison. H–I: Real-time PCR analysis of VEGF-B167 (H) and 186 (I) expression shows that mRNA expression levels of
VEGF-B167 and 186 in the AAV-VEGF-B167 and 186 groups are significantly higher than those in the AAV-GFP control group (in arbitrary
units normalized against mouse β-actin; *p<0.05, **p<0.001). Data are espressed ±SEM and sample sizes were 3. B–G: Scale bar represents
50 µm.
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497Figure 2. No obvious induction by vascular endothelial growth factor (VEGF)-B167 or 186 of inflammatory response 4 weeks after subretinal
injection of adeno-associated virus (AAV)-VEGF-B167 and 186 in C57BL/6J mice. A–C: Hematoxylin and eosin staining; D–G: Leukostasis
assay indicated that neither AAV-VEGF-B167 (E, G) nor AAV-VEGF-B186 (F, G) caused significant retinal leukostasis compared to the AAV-
GFP control (D). Data are presented as mena±SEM. Sample sizes for GFP and VEGF-B167 are 10 and for VEGF-B186 is 8. For GFP versus
VEGF-B167, p=0.13; for GFP versus VEGF-B186, p=0.3. H: An image for comparison showing vascular endothelial growth factor (VEGF)-
A-induced leukostasis 6 h after intravitreal administration of 1×10−6 M VEGF-A. Arrows are pointing to leukocytes adhering to the vessel
wall. Original magnification was ×20.
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498the  AAV-VEGF-B167,  AAV-VEGF-B186,  and  AAV-GFP-
treated eyes in an experimental model of CNV. Four weeks
after vector injection and two weeks after rupture of Bruch’s
membrane with laser photocoagulation, the area of CNV at
Bruch’s membrane rupture sites appeared larger in eyes that
had been given subretinal injections of AAV-VEGF-B167 or
AAV-VEGF-B186 (Figure 4A,B) when compared with those
given  a  subretinal  injection  of  AAV-GFP  (Figure  4C).
Measurement of the area of CNV at rupture sites by image
analysis,  with  the  investigator  masked  with  respect  to
treatment group, confirmed that the mean area of CNV was
significantly greater in eyes given subretinal injections of
either AAV-VEGF-B167 (0.019±0.003 mm2, n=22, p=0.02) or
AAV-VEGF-B186 (0.021±0.017 mm2, n=19, p=0.02) (Figure
4D)  when  compared  with  eyes  given  AAV-GFP
(0.012±0.002  mm2,  n=20)  by  the  corresponding  route  of
administration.
Both  VEGF-B167  and  VEGF-B186  increased  retinal
neovascularization in oxygen induced ischemic retinopathy:
Given  that  overexpression  of  VEGF-B167  and  186
significantly increased the area of CNV, we next explored
whether they would increase the area of pathological retinal
NV. Developing retinal NV in the mouse model of OIR has
proven reliable and quantifiable over 17 days, and is widely
used  to  clarify  the  molecular  changes  in  neovascular  eye
diseases and to screen anti-angiogenic compounds [79-81]. At
P7, pups received an intravitreal injection of AAV-VEGF-
B167, AAV-VEGF-B186, or AAV-GFP vectors and were then
placed in a 75% oxygen box for 5 days. Thereafter, pups were
returned to room air for another 5 days. At day 3, 6, 8, and 10
after  vector  delivery,  three  AAV  GFP-injected  pups  were
killed  to  observe  the  GFP  protein  expression,  which  was
initially and focally seen in the retina at day 3, and became
stronger  and  more  diffuse  at  day  6  and  10  (Figure  5).
Therefore, protein expression of the GFP reporter gene at the
above time points indicated that AAV VEGF-B167 or 186
could also effectively be expressed at these time points. At
P17 (10 days after receiving the AAV vectors), increased
expression of VEGF-B was also confirmed in AAV-VEGF-
B-injected pups by quantitative PCR. At P17, mice treated
with  AAV-VEGF-B167  (18.6%±2.1%,  n=10,  p<0.001)  or
AAV-VEGF-B186 (16.2%±0.89%, n=8, p=0.001) developed
more extensive retinal NV than control mice treated with
AAV-GFP (9.97% ± 1.3%, n=13; Figure 6A-D).
DISCUSSION
Overexpression of VEGF-B can be achieved using an AAV
vector, and the source of the gene product is widespread in the
retina. Both intravitreal and subretinal administration of the
vector were effective, with subretinal administration leading
to the greatest increase in VEGF-B expression in adult mice.
In adult mice, intravitreal administration was not as effective
as subretinal delivery (data not shown). That is why we chose
subretinal delivery in adult mice. However, in pups, whose
Figure 3. Increased vasopermeability of retinas from B186 but not from B167 vascular endothelial growth factor. Quantitative blood brain
barrier (BRB) assays were performed as described in Methods following subretinal injection of AAV-VEGF-B167, AAV-VEGF-B186, or
AAV-green fluorescent protein (GFP) control vectors in C57BL/6J mice. The retina to lung leakage ratio is shown in A; the retina to renal
leakage ratio is shown in B. Each bar represents the mean (±SEM) ratio of CPM per milligram of retina to CPM per milligram of lung or
kidney. Sample sizes for A: GFP is n=5; VEGF-B167 is n=8; VEGF-B186 is n=7. B: GFP is n=7; VEGF-B167 is n=8; VEGF-B186 is n=9.
P-values for the retina to lung leakage ratio relative to GFP were 0.10 for VEGF-B167 and 0.04 for VEGF-B186. P-values for the retina to
renal leakage ratio relative to GFP were 0.05 for VEGF-B167 and 0.03 for VEGF-B186, determined by unpaired t test, from the GFP control
retinas.
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499retinas  are  still  developing  and  whose  inner  limiting
membranes are not yet well developed, the vector can easily
penetrate  the  entire  retina  from  the  vitreous;  therefore,
intravitreal administration of the vectors was implemented,
since  it  yielded  the  same  expression  profile  and  was
technically less difficult than subretinal injection in neonates.
Previous attempts have been made using an adenovirus vector,
which resulted in phenotypic changes such as retinal folding
and occasional CNV, but these effects were largely due to an
inflammatory  response  caused  by  the  adenovirus  vector.
Inflammation was eliminated by using the AAV vector, so that
the true effect of VEGF-B could be evaluated.
The functions of VEGF-B in normal and pathological
conditions  are  poorly  understood,  but  since  it  binds  to
VEGFR1, as does PlGF, it was thought that these activities
might be similar to those of PlGF. AAV vector constructs
were generated to investigate whether VEGF-B promoted
pathological  angiogenesis  and  inflammation,  as  did  PlGF
[22,29,32],  and  whether  its  overexpression  elicited  any
phenotypic changes in the retina. The vasoproliferative and
vasopermeability  activities  of  VEGF  have  generally  been
attributed to VEGFR2, but the finding that anti-PlGF inhibits
pathological  angiogenesis  [22]  shows  that  VEGFR1  also
plays a role. The present study shows that overexpression of
VEGF-B enhances retinal NV resulting from ischemia and
Figure 4. Increased choroidal neovascularization caused by overexpression of adeno-associated virus-vascular endothelial growth factor
(AAV-VEGF)-B167 and 186 at rupture sites in Bruch’s membrane. A–C: Two weeks after subretinal injection of AAV-VEGF-B167 (A), AAV-
VEGF-B186 (B), or AAV-GFP (C), mice underwent laser photocoagulation that ruptured Bruch’s membrane in three locations in each eye.
Fourteen  days  later,  mice  were  perfused  with  fluorescein-labeled  dextran,  and  choroidal  flatmounts  were  prepared  and  examined  by
fluorescence microscopy. Compared to eyes treated with a subretinal injection of AAV-GFP (C), the area of choroidal neovascularization at
Bruch’s membrane rupture sites was significantly increased in eyes given a subretinal injection of AAV-VEGF-B167 (A, D) or 186 (B, D).
The arrows define the limits of the choroidal neovascularization. D shows that the area of choroidal neovascularization (CNV), expressed in
mm2, is significantly increased following a subretinal injection of AAV-VEGFB-B167 or 186. Data are expressed as mean±SEM. Statistical
comparisons were made by unpaired t test (*p<0.05). Images A to C have the same scale. Scale bar represents 100 μm.
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500CNV following laser treatment, providing further evidence
that  VEGFR1  plays  a  role  and  suggesting  that  PlGF  and
VEGF-B  share  signaling  mechanisms.  The  finding  that
VEGF-B is highly expressed in the CNV area, 7 days after
laser treatment, and that anti-VEGF-B reduces CNV, supports
the  conclusions  about  its  role  in  CNV  formation  and  its
potential as a target molecule [58].
Previous studies have reported apparently contradictory
results on the angiogenic properties of VEGF-B, with findings
varying from VEGF-B having no angiogenic effect at all
[42,51,53] to its promotion of unrestricted angiogenesis [47],
its ability to potentiate rather than induce angiogenesis when
it is transgenically expressed in endothelial cells [49], or its
ability to induce selective revascularization of the ischemic
myocardium but not the revascularization of other organs
[54,55]. We have previously reported that when VEGF-B is
injected into the nonischemic myocardium, it elicits only a
modest angiogenic response consisting of the generation of
Figure  5.  Representative  images  show  transgene  expression  after  intravitreous  delivery  of  recombinant  adeno-associated  virus-green
fluorescent protein (AAV-GFP) in the oxygen induced ischemic retinopathy (OIR) model. At postnatal day 7, pups received an intravitreal
injection of AAV-GFP vector and were then placed in a 75% oxygen box for 5 days. Thereafter, pups were returned to room air for another 5
days. At day 10 after injection (postnatal day 17), pups were killed. Choroidal flatmounts (A, B) and cryosections (C, D) were prepared. Green
fluorescent protein expression was directly observed using fluorescence microscopy. Original magnifications were as follows: A: ×5, B: ×40,
C, D: ×20. The figure shows increased expression of the reporter gene, GFP. The following layers are illustrated: RPE: retinal pigmental
epithelium, OS: outer segment, OPL: outer plexiform layer, INL: inner nuclear layer, IPL: inner plexiform layer, GCL: ganglion cell layer.
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501enlarged vessels devoid of α-SMA-positive cells [56,57]. Our
work here demonstrates that both of the VEGF-B isoforms
exert  a  significant  angiogenic  effect  under  conditions  of
ocular  damage,  potentiating  pathologic  blood  vessel
formation in animal models of CNV and retinal NV. Previous
studies that failed to show an angiogenic effect of VEGF-B
evaluated different systems, used a different type of vector
(adenovirus), or administered the protein, rather than the gene.
It appears clear that the retina and heart respond differently to
the  overexpression  of  VEGF-B.  The  adenovirus  vector  is
proinflammatory, and the influence of inflammatory cells may
alter the effect of VEGF-B. It could also be that continuous
exposure  to  elevated  VEGF-B  levels  achieved  by  gene
transduction,  rather  than  by  intermittent  increases  from
injections of the protein, is necessary for revealing VEGF-B’s
angiogenic effect in the retina and choroid. This possibly
explains why the present study’s results differ from those of
earlier studies in which the absence of an angiogenic effect
was observed following the injections of VEGF-B protein
[58]. Zhang et al. [58] showed that blocking VEGF-B resulted
in the inhibition of CNV and retinal NV. The present study
clearly shows that increased expression of VEGF-B enhances
choroidal and retinal NV.
Figure 6. Both vascular endothelial growth factor-B167 and 186 increased retinal neovascularization in oxygen induced ischemic retinopathy.
At postnatal day 7 (P7), pups received an intravitreal injection of AAV-VEGF-B167, AAV-VEGF-B186, or AAV-GFP vectors, then were placed
in a 75% oxygen box for 5 days and returned to room air at P12 for another 5 days. At P17, mice were sacrificed, retinal-whole mounts
prepared, and retinal neovascularization quantified as described in Methods. Images from A to C are representative retina whole mounts from
mice that received AAV-GFP (A), AAV-VEGF-B167 (B), or AAV-VEGF-B186 (C). Original magnification was ×5. All images were taken
under the same conditions for optimal comparison. D: Statistical analysis indicated that both isoforms of VEGF-B significantly increased the
retinal neovascularization area compared with the GFP control group. The graph shows that AAV-VEGF-B167 and 186 promote increased
retinal neovascularization in the oxygen induced ischemic retinopathy model. Data are expressed as mean±SEM.
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502We  also  showed  that  VEGF-B186  promotes  vascular
permeability, confirming the role of VEGFR1 in this activity
as well. The finding that VEGF-B167 does not significantly
increase vascular permeability, although our results do appear
to show a trend in that direction, is likely due to the greater
capacity of VEGF-B186 to diffuse through the retinal tissue
due to the absence of the heparin-binding moiety. With a
greater  sample  size,  VEGFB-167  will  also  possibly
demonstrate a significant increase in vascular permeability,
but  this  effect  is  enhanced  by  the  186  isoform.  The  pro-
inflammatory activity of VEGF has generally been associated
with  VEGFR1,  but  VEGF-B  does  not  appear  to  be  pro-
inflammatory, even though anti-PlGF inhibits inflammatory
infiltration into CNV lesions [22]. This observation further
supports  the  conclusion  that  VEGF-B  and  PlGF  activate
VEGFR1 in a subtly different manner, possibly through the
use of different coreceptors.
The present study gives insight into the isolated effect of
VEGF-B on the retina and choroid in the absence of disease-
associated  stimuli  or  stimuli  that  normally  cause  VEGF
upregulation. In DR, neovascular AMD, and retinal vasculitis,
VEGF  upregulation  is  seen  with  inflammation,  and  if  an
intravitreal VEGF inhibitor is administered, the inflammation
is reduced. This leads to the suspicion that VEGF is a primary
inflammatory mediator in these inflammatory disorders and
that VEGF may simply be a mediator that compromises the
BRB,  allowing  cytokines,  antibodies,  complement,  and
leukocytes to leave the blood stream if there is the appropriate
stimulus for doing so [82,83]. The present study demonstrates
that, if there is no primary cause of inflammation, then the
opening of the BRB will not, by itself, cause inflammation.
Upregulation of VEGF-B, to our knowledge, has not been
clinically demonstrated in ocular disease, but it has in renal
cell  carcinoma  [84].  The  finding  that  VEGF-B  promotes
retinal and choroidal NV and BRB breakdown suggests that
VEGF-B  may  contribute  to  the  complications  of
vasoproliferative  ocular  disorders  and  that  it  could  be  a
therapeutic target for treating angiogenic ocular disorders and
disorders leading to macular edema.
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